Dose-escalating vinblastine for the treatment of canine mast cell tumour

Veterinary and Comparative Oncology

Volumn 6, Issue 2, 2008, Pages 111-119

  Vickery, K R ^a   Wilson, H ^b   Vail, D M ^b   Thamm, D H ^a,c  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Chemotherapy; Dog; Mastocytoma; Vinca alkaloid

Indexed keywords

CANIS FAMILIARIS; VINCA;

ANTINEOPLASTIC AGENT; VINBLASTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DOSE RESPONSE; FEMALE; MALE; METASTASIS; MORTALITY; SARCOMA; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MAST-CELL SARCOMA; NEOPLASM METASTASIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 61749104434     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2007.00147.x     Document Type: Article

References (17)

1. Withrow SJ and MacEwen EG. In: Small Animal Clinical Oncology, 3rd edn., Philadelphia, W.B. Saunders, 2001: 718.
2. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. Journal of Small Animal Practice 1973;14: 27-41.
3. Patnaik AK, Ehler WJ and MacEwen EG. Canine cutaneous mast cell tumour: morphologic grading and survival time in 83 dogs. Veterinary Pathology 1984;21: 469-474.
4. Hottendorf GH and Nielsen SW. Pathologic survey of 300 extirpated canine mastocytomas. Zentralblatt für Veterinärmedizin. Reihe A 1967;14: 272-281.
5. Simoes JP, Schoning P and Butine M. Prognosis of canine mast cell tumours: A comparison of three methods. Veterinary Pathology 1994;31: 637-647.
6. Thamm DH, Mauldin EA and Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumour -41 cases (1992-1997). Journal of Veterinary Internal Medicine 1999;13: 491-497.
7. Turrel JM, Kitchell BE, Miller LM and Iheon A. Prognostic factors for radiation treatment of mast cell tumour in 85 dogs. Journal of the American Veterinary Medical Association 1988;193: 936-940.
8. Ayl RD, Couto CG, Hammer AS, Weisbrode S, Ericson JG and Mathes L. Correlation of DNA ploidy to tumour histologic grade, clinical variables, and survival in dogs with mast cell tumours. Veterinary Pathology 1992;29: 386-390.
9. Thamm DH, Turek MM and Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Journal of Veterinary Medical Science 2006;68: 581-587.
10. Trumel C, Bourges-Abella N, Touron C, Lanore D, Geffre A, Diquelou A, Guelfi JF and Braun JP. Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: A retrospective study in 14 dogs with mast cell tumours. Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine 2005;52: 275-279.
11. Davies DR, Wyatt KM, Jardine JE, Robertson ID and Irwin PJ. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumours. Journal of the American Animal Hospital Association 2004; 40: 124-130.
12. Singh J, Rana JS, Sood N, Pangawkar GR and Gupta PP. Clinico-pathological studies on the effect of different anti-neoplastic chemotherapy regimens on transmissible venereal tumours in dogs. Veterinary Research Communications 1996;20: 71-81.
13. Vail DM. Veterinary co-operative oncology group -common terminology criteria for adverse events following chemotherapy or biological antineoplastic therapy in dogs and cats. Veterinary and Comparative Oncology 2004;2: 194-213.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000;92: 205-216.
15. Laing EJ, Fitzpatrick PJ, Binnington AG, Norris AM, Mosseri A, Rider WD, Valli VE and Baur A. Half-body radiotherapy in the treatment of canine lymphoma. Journal of Veterinary Internal Medicine 1989;3: 102-108.
16. Golden DL and Langston VC. Uses of vincristine and vinblastine in dogs and cats. Journal of the American Veterinary Medical Association 1988;193: 1114-1117.
17. Creasey WA, Scott AI, Wei CC, Kutcher J, Schwartz A and Marsh JC. Pharmacological studies with vinblastine in the dog. Cancer Research 1975;35: 1116-1120.